Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery
Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
Stocks · News reference
Deal Dispatch: Bending Spoons Acquires Miro For $1.35B, Kinetik Up For Sale, LIV Golf Bankruptcy
Read this week's top deal updates, including Bending Spoons' Miro deal, Chime's Stride Bank purchase, and the LIV Golf bankruptcy.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bending Spoons Announces Date for Q3 2026 Financial Results
Bending Spoons S.p.A. has scheduled the release of its third-quarter 2026 financial results for November 20, 2026.
Growth Lead Sectors In Friday Trading As Defensives Trail
Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
Ozempic Market to Reach USD 113.95 Billion as Demand for GLP-1 Therapies Accelerates, Reports Mordor Intelligence
The Ozempic market is projected to grow from USD 30.04 billion in 2026 to USD 113.95 billion by 2032, with a CAGR of 24.89%. Growth is driven by expanding diabetes treatment demand, broader metabolic health applications, and increasing adoption of GLP-1 therapies. North America leads the market, while Asia-Pacific emerges as a significant growth region. Key challenges include treatment affordability, reimbursement restrictions, and supply-chain requirements.
Bending Spoons to announce Q3 2026 results
Bending Spoons S.p.A. (Nasdaq: BSP) announced it will release Q3 2026 financial results on November 20, 2026, followed by a conference call and webcast at 8:00 am ET. The company, which specializes in acquiring and transforming digital businesses, continues its strategy of operational excellence and sustainable earnings expansion through acquisitions.
Eli Lilly Enters Agreement with Hims & Hers to Expand Access to Obesity Medications
Eli Lilly and Company has reached an agreement with Hims & Hers to provide patients with direct access to its FDA-approved obesity medications, Zepbound and Foundayo, through the Hims & Hers platform.